Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.
Multiple myeloma is an incurable hematologic cancer characterized by the clonal proliferation of malignant plasma cells within the bone marrow. Numerous studies suggest that the myeloma plasma cells occupy and alter the stromal tissue of the bone marrow as a means of enhancing their survival and growth. However, the nature and magnitude of the changes to the stromal cell tissue remain to be determined. In this study, we used mesenchymal stromal cell and osteoblast-related cell surface marker expression (STRO-1 and alkaline phosphatase, respectively) and flow cytometry to enumerate mesenchymal stromal cell and osteoblast numbers in bone marrow recovered from myeloma patients at the time of diagnosis. Using this approach, we identified an increase in the number of STRO-1 positive colony forming mesenchymal stromal cells and a concomitant decrease in alkaline phophatase osteoblasts. Notably, this increase in mesenchymal stromal cell numbers correlated closely with plasma cell burden at the time of diagnosis. In addition, in comparison with the osteoblast population, the STRO-1+ mesenchymal stromal cell population was found to express higher levels of plasma cell- and osteoclast-activating factors, including RANKL and IL-6, providing a mechanism by which an increase in mesenchymal stromal cells may promote and aid the progression of myeloma. Importantly, these findings were faithfully replicated in the C57BL/KaLwRij murine model of myeloma, suggesting that this model may present a unique and clinically relevant system in which to identify and therapeutically modulate the bone microenvironment and, in turn, alter the progression of myeloma disease.
andrew.zannettino@health.sa.gov.au.
Jacqueline E
JE
Noll
Sharon A
SA
Williams
Christine M
CM
Tong
Hongsheng
H
Wang
Julie M
JM
Quach
Louise E
LE
Purton
Katherine
K
Pilkington
Luen B
LB
To
Andreas
A
Evdokiou
Stan
S
Gronthos
Andrew C W
AC
Zannettino
D000818:Animals; D000954:Antigens, Surface / Q000378:metabolism; D001853:Bone Marrow / Q000378:metabolism* / Q000473:pathology*; D049109:Cell Proliferation; D004195:Disease Models, Animal; D006801:Humans; D016130:Immunophenotyping; D008222:Lymphokines / Q000378:metabolism; D059630:Mesenchymal Stem Cells / Q000378:metabolism*; D051379:Mice; D008998:Monoclonal Gammopathy of Undetermined Significance / Q000378:metabolism / Q000473:pathology; D009101:Multiple Myeloma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D010950:Plasma Cells / Q000378:metabolism* / Q000473:pathology; D012720:Severity of Illness Index; D059016:Tumor Microenvironment; D014410:Tumor Stem Cell Assay
D000954:Antigens, Surface; D008222:Lymphokines; C525591:STRO-1 antigen, human; C008718:osteoclast activating factor